INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced results from a Phase 3b clinical trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in ...
Eli Lilly and Company LLY, last week, gained the much-anticipated FDA approval for its once-daily oral GLP-1 pill ...
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also ...
INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use ...
For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug before it could work—forcing millions of patients to rely on daily injections.
If you've been around the skincare block as many times as I have, peptides will be nothing new to you. Everyone from No7, to The Inkey List to Olay includes the ingredient in their serums and ...
Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in now. Eli Lilly and Company (NYSE:LLY) announced on March 28 detailed results from the TOGETHER-PsA open-label Phase 3b ...
One of these companies' lineup and pipeline within weight management and outside look much stronger. Valuation does not tip the scale in the other's favor. Eli Lilly's weight loss medicine, Zepbound, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results